编号/登记号：
NCT03534453
注册时间：
2018-05-23
研究开始时间：
2018-05-29
研究结束时间：
2023-10-01
项目类型：
clinicaltrials临床试验
本院角色：
牵头单位
多中心研究：
国际多中心
参与国家：
Malaysia;China
招募状态：
Active,not recruiting
试验分期：
III期
研究疾病/适应症：
Relapsed Ovarian Cancer;Following Complete or Partial Response to Platinum Based Chemotherapy;Platinum Sensitive
研究类型：
Interventional
研究单位：
[1]Tongji Hospital, Tongji Medical College of Huazhong University of Sicence and Technology
[2]AstraZeneca
[3]Research Site,Beijing,China,100142
[4]Research Site,Changsha,China,410013
[5]Research Site,Chengdu,China,610041
[6]Research Site,Chongqing,China,400030
[7]Research Site,ChongQing,China,400038
[8]Research Site,Hangzhou,China,310006
[9]Research Site,Hangzhou,China,310022
[10]Research Site,Harbin,China,150081
[11]Research Site,Hefei,China,230031
[12]Research Site,Jinan,China,250012
[13]Research Site,Shanghai,China,200011
[14]Research Site,Shanghai,China,200032
[15]Research Site,Shanghai,China,200080
[16]Research Site,Shenyang,China,110016
[17]Research Site,Tianjin,China,300060
[18]Research Site,Tianjin,China
[19]Research Site,Wuhan,China,430079
[20]Research Site,Xian,China,710061
[21]Research Site,Zhengzhou,China,450008
[22]Research Site,Johor Bahru,Malaysia,81100
[23]Research Site,Kuala Lumpur,Malaysia,59100
[24]Research Site,Kuala Lumpur,Malaysia
[25]Research Site,Kuching,Malaysia,93586
[26]Research Site,Putrajaya,Malaysia
关键词：
ovarian cancer
PARP Inhibitor
Platinum sensitive
研究目的：
This is a prospective, open-label, single arm, multi-centre interventional study to assess the clinical efficacy and safety of olaparib maintenance monotherapy and will be conducted in patients with platinum sensitive relapsed (PSR) high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy
